About E25Bio
E25Bio is a Healthcare company based in Cambridge (United States) founded in 2018 by Irene Bosch and Bobby Brooke Herrera. It operates as a diagnostic platform for disease detection and mapping is provided. E25Bio has raised $4.8 million across 6 funding rounds from investors including Khosla Ventures, Gates Foundation and HHS. The company has 5 employees. Its chief executive is Irene Bosch. E25Bio offers products and services including Slot Games, Live Casino, and Sports Betting. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Viral. Its competitors include Souzhou Ribo Life Science, Senzo, PathoQuest, Hememics Biotechnologies and Quantalife and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
E25Bio was founded in 2018 in Cambridge, United States, within the health diagnostics sector. A point-of-care device is developed for analyzing protein variations in blood samples to detect dengue, zika, and chikungunya. Disease outbreaks are predicted through this platform, which supports real-time analysis for clinical decisions and treatment planning. Operations focus on enabling professionals to map and identify diseases accurately.
- Headquarters Cambridge, United States
- Employees 5
- Founders Irene Bosch, Bobby Brooke Herrera
- SectorsHealthcare
- Email••••••••
- Website e25bio.com
- Social LinkedIn
- Total Equity Funding$4.8M (USD)
in 6 rounds
- Latest Funding Round$500K (USD), Seed
May 2021
- InvestorsKhosla Ventures
& 5 more
- Employee Count5
Products & Services of E25Bio
E25Bio offers a comprehensive portfolio of products and services, including Slot Games, Live Casino, and Sports Betting.
Platform for playing digital slot games from various providers
Real-time interactive casino games for users
Online wagering on sports events and outcomes
Funding Insights of E25Bio
E25Bio has successfully raised a total of $4.8M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $500 thousand completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.8M
- Total Rounds 6
- Last Round Seed — $500,000
- First Round $150,781
(Aug 2019)
- Investors Count 6
All 6 funding rounds of E25Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $500,000 | Seed | – | – | – |
| Aug 2020 | $4.14M | Grant | – | – | |
| Mar 2020 | $2M | Seed | – | Khosla Ventures | – |
| Aug 2019 | $2.3M | Seed | – | Engine | |
| Aug 2019 | $1.43M | Grant | – | – | |
| Aug 2019 | $150,781 | Grant | – | – |
6 investors in total: 5 institutional and 1 angel.
Investors in E25Bio
E25Bio has secured backing from 6 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Khosla Ventures, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
VC funding and acceleration support are provided to tech startups. | – | engine.xyz | Cambridge, United States | |
Venture capital investing and portfolio management services for accredited investors. | – | av.vc | - | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
AC Alejandro Chavez | - | – | unknown_ee7a67156279496e8 | - |
Investor details for E25Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of E25Bio
7 people are tracked at E25Bio (3 in leadership, 1 in board & advisors, 3 in team); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Irene Bosch | Founder & CEO | Leadership |
Bobby Brooke Herrera | Co-Founder & CSO | Leadership |
Carlos-Henri Ferré | Director, Operations & Communications | Leadership |
Lee Gehrke | Co-Founder & Advisor | Board & advisors |
Nidhi Nandu | Research Scientist I | Team |
Jordan Harrison | Research Associate I | Team |
Brena Sena | Clinical Trial Lead & Regulatory Affairs Manager | Team |
Complete people profiles for E25Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of E25Bio
3 dated milestones of E25Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded E25Bio is founded.
- Funding First funding round of $151K.
- Funding Latest funding round, Seed, of $500K.
Competitors of E25Bio
E25Bio has 8 listed competitors in our database, 7 of them funded. They include Souzhou Ribo Life Science, Senzo, PathoQuest, Hememics Biotechnologies and Quantalife, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ribolia.com | 2007 | Suzhou, China | $200.79M | – | Nucleic acid drugs are developed via RNA interference technology. | |
| senzo.com | 2013 | San Francisco, United States | $9.6M | 13 | Point-of-care diagnostic devices for infectious diseases are developed. | |
| pathoquest.com | 2010 | Paris, France | $9.99M | – | Next-generation sequencing is provided for microbiology testing applications. | |
| hememics.com | 2009 | Gaithersburg, United States | $4.6M | 13 | Biopreservation platform for mammalian cells and biologics is developed. | |
| quantalife.com | 2008 | Pleasanton, United States | $28.71M | – | Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. | |
| matridx.com | 2019 | Hangzhou, China | – | – | Sequencing-based platform for microorganism detection in patients is developed. | |
| incelldx.com | 2009 | Menlo Park, United States | $9.5M | – | Molecular diagnostic assays and kits for infectious diseases are developed. | |
| daktaridx.com | 2008 | Boston, United States | $73.42M | 23 | Point of care diagnostic platform and data management system |
Detailed competitors of E25Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as E25Bio (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about E25bio
Complete news archive for E25Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about E25Bio
E25Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
E25Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Irene Bosch is the current CEO of E25Bio. They have also founded this company.
E25Bio is a funded company, having raised a total of $4.8M across 6 funding rounds to date. The company's 1st funding round was a Grant of $150.78K, raised on Aug 2019.
E25Bio has 5 employees.
E25Bio was founded in 2018 in Cambridge, United States, within the health diagnostics sector. A point-of-care device is developed for analyzing protein variations in blood samples to detect dengue, zika, and chikungunya. Disease outbreaks are predicted through this platform, which supports real-time analysis for clinical decisions and treatment planning. Operations focus on enabling professionals to map and identify diseases accurately.
E25Bio's top competitors include Souzhou Ribo Life Science, Quantalife and Senzo.
E25Bio offers Slot Games, Live Casino, and Sports Betting.
E25Bio has 6 investors. Key investors include Khosla Ventures, Gates Foundation, HHS, The Engine, and Alejandro Chavez.